Annovis Bio (ANVS) Soars After New Parkinson’s Biomarker Data Show Buntanetap Halts Cognitive Decline – November 17, 2025
Annovis Bio reported new Phase 3 data showing its drug buntanetap halted cognitive decline in early Parkinson’s patients and improved Alzheimer’s-related biomarkers in a key subgroup with amyloid co-pathology. Shares of ANVS surged following the announcement. The company plans to present full biomarker results at the CTAD 2025 conference in December.
